RELATIONSHIP BETWEEN INSULIN-LIKE GROWTH FACTOR TYPE 1 AND INTRAUTERINE GROWTH

Lidija Banjac1, Jelena Kotur-Stevuljević2, Tamara Gojković2, Vesna Bokan-Mirković3, Goran Banjac4 and Gorica Banjac5

1Department of Neonatology, Clinical Center of Montenegro, Podgorica, Montenegro; 2Institute of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia; 3Center for Physical Medicine and Rehabilitation, Clinical Center of Montenegro, Podgorica, Montenegro; 4Institute of Children’s Diseases, Clinical Center of Montenegro, Podgorica, Montenegro; 5The Obstetrics and Gynaecology Clinic Narodni Front, Belgrade, Serbia

SUMMARY - Insulin-like growth factor 1 (IGF-1) is a regulator of intrauterine growth, and circulating concentrations are reduced in intrauterine growth-restricted fetuses. The aim of our study was to investigate the relationship between IGF-1 levels in newborns and intrauterine growth, expressed as birth weight (BW). The research was designed as a cross-sectional study. The study included 71 premature newborns, gestational age (GA) ≤33 weeks. Quantitative determination of IGF-1 was performed in the 33rd post-menstrual week (pmw) to make the measurements more comparable. We used an enzyme-bound immunosorbent test for quantitative determination of IGF-1. Our results showed the mean IGF-1 level in premature newborns in 33rd pmw to be 23.1±4.56 (range 15.44-39.75) μg/L. There was no difference in IGF-1 values between male (23.1±4.98 μg/L) and female (23.1±4.87 μg/L) newborns. There was no significant difference in the average IGF-1 levels between male and female newborns with BW <50th and BW >50th percentile for GA either (p>0.50). Only BW <33rd percentile newborns had a statistically significantly lower IGF-1 level compared to newborns with greater BW. Based on our results, it is concluded that serum IGF-1 level reflects intrauterine growth only in BW <33rd percentile newborns. This fact could be used for further therapeutic purposes.

Key words: Infant, newborn; Insulin-like growth factor I; Fetal growth retardation; Cross-sectional studies

Introduction

Intrauterine growth restriction (IUGR) is usually the end result of maternal, placental, fetal and genetic causes. Endocrine environment controls the growth of the fetus and endocrine causes are responsible for IUGR development1. Multiple hormonal interactions are able to produce a specific pattern of intrauterine development with potential lifelong consequences for health2. Fetal endocrine system also plays a significant role in helping the fetus adjust to extrauterine environment3–3.

Insulin-like growth factor 1 (IGF-1) is a polypeptide hormone produced mainly by the liver in response to the endocrine growth hormone stimulus, but it is also secreted by multiple tissues for autocrine/paracrine purposes. During fetal life, IGF-1 is mostly secreted in the placenta4. IGF-1 possesses a wide number of own activities such as anabolic, antioxidant, anti-inflammatory and cytoprotective actions5. Many authors have investigated the relationship between IGF-1 and diseases of prematurity6,7. IGF-1 is an important regulator of fetal growth, and circulating concentrations are reduced in intrauterine growth-re-
The latest studies have shown positive correlation between birth weight (BW), gestational age (GA) and umbilical cord serum IGF-1 levels. Also, these studies have shown that in humans, IUGR is correlated to high levels of serum IGF binding protein-1 (IGFBP-1). The IGFBP system is involved in fetal growth, bone mineralization, and energetic status in humans. The IGFs are necessary for normal brain development and function, and may affect brain growth and neurologic development.

The list of roles of IGF-1 is increased, both in physiological and pathological conditions, underlying that its potential therapeutic options seem to be limited to those proven states of local or systemic IGF-1 deficiency as a replacement treatment, rather than increasing its upper normal range.

The aim of the study was to investigate the relationship between IGF-1 levels in newborns and intrauterine growth expressed as BW, and secondly to determine whether there was a difference in IGF-1 levels between male and female newborns.

Materials and Methods

This study was performed at Department of Neonatology, Clinical Center of Montenegro, Podgorica, after approval from the institutional Ethics Committee. The mothers signed an informed consent to participate in the study. The study was designed as a cross-sectional study. The study included 71 premature newborns, GA ≤33 weeks, hospitalized at Department of Neonatology, Clinical Center of Montenegro. Newborns with conspicuous congenital anomalies were not included in the study.

A database was formed including demographic data, data from pregnancy and delivery (GA) and anthropometric measures at birth (BW). In every newborn included in the study, venous blood sample (0.5 mL) was obtained in 33rd postmenstrual week (pmw) to make the measurements more reliable and comparable. The samples (serum) were frozen and stored in a freezer (-80 °C) until completion of a series of samples. In all samples, quantitative determination of the requested biomarker (IGF-1) was performed simultaneously, under the same conditions, using immunochemical enzyme-linked immunoosorbent assay (ELISA), a method widely used on this hormone measurement.

For percentile average BW of male/female infants, we used the RCPCH UK-WHO Neonatal and Infant Close Monitoring Growth Chart. Based on these growth charts, male and female newborns were divided into two subgroups of newborns with BW below the 50th percentile (BW <50th) for GA and newborns with BW above the 50th percentile (BW >50th) for GA. We compared the mean levels of IGF-1 between the groups.

In the second step, we determined the 33rd percentile (1481 g) of BW for the whole group of newborns and obtained two groups of BW below the 33rd percentile (BW <33rd) and BW above the 33rd percentile (BW >33rd). We compared the levels of IGF-1 between the groups.

Statistical data processing included calculation of descriptive measures, use of statistical tests and statistical software programs (IBM, SPSS) for comparisons of parameters between the subgroups. Normality of data was tested by Kolmogorov-Smirnov test. The following statistical tests were used: Student’s t-test, ANOVA test, Kruskal-Wallis test with distinct post-hoc tests (Tukey test for parametric ANOVA and Mann-Whitney U test for Kruskal-Wallis non-parametric test). Univariate associations were evaluated using Pearson’s correlation analysis. In all tests used, the level of statistical significance was set at p<0.05.

Results

There were 42 (59.15%) male and 29 (40.85%) female newborns. The mean BW of newborns in primary cohort was 1708.4±403.64 (range 990-2860) g, mean GA 31.2±1.87 (range 26-33) gestational weeks, and mean IGF-1 level 23.1±4.56 (range 15.44-39.75) mcg/L. Average BW (in grams) and percentiles of BW in groups with the same GA are shown in Tables 1 and 2. Table 3 shows BW, GA and IGF-1 levels of male and female newborns. Student’s t-test revealed difference in BW, GA and IGF-1 level. Male newborns had a significantly higher BW, but there was no sex difference in GA. There was no difference in the levels of IGF-1 between male (23.2±4.98 mcg/L) and female (23.1±4.87 mcg/L) newborns (p>0.05; t=1.284).

To further explore the relationship of BW and IGF-1, we divided each group of participants (male and
female) into two subgroups of newborns with BW <50th percentile and newborns with BW >50th percentile.

There were 18 male newborns with BW <50th percentile and their mean BW was 1588.3±244.06 g. There were 24 male newborns with BW >50th percentile and their mean BW was 1951.7±444.70 g.

There were 10 female newborns with BW <50th percentile and their mean BW was 1446±295.57 g. There were 19 female newborns with BW >50th percentile and their mean BW was 1653.2±382.33 g.

Gestational age and serum levels of IGF-1 are shown in Tables 4 and 5. The subgroups of male infants did not differ according to GA (p>0.05; t=1.801) and there was no significant difference in the levels of IGF-1 (p>0.05; t=2.064) either. The subgroups of female newborns did not differ according to GA (p>0.05; t=1.745) and there was no significant difference in the levels of IGF-1 (p>0.05; t=2.758).

In the next step, the male and female groups were divided into two subgroups according to the cut-off 33rd percentile (1481 g) of BW and compared according to IGF-1 levels (Tables 6 and 7).

Tables 6 and 7 show the values of GA and IGF-1 in male and female newborns below (BW <33rd) and above (BW >33rd) the 33rd percentile of BW. There

---

**Table 1. Average percentiles of birth weight (BW, grams) in male newborns (N=42) in groups of the same gestational age (GA)**

| GA (weeks) | <10th percentile n BW (g) | <31st percentile n BW (g) | <50th percentile n BW (g) | <66th percentile n BW (g) | <90th percentile n BW (g) |
|------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| ≤28        | <890                      | <1080                     | <1150                     | <1200                     | <1400                     |
| 29         | <1000                     | <1150                     | <1290                     | <1350                     | <1590                     |
| 30         | <1110                     | <1350                     | <1425                     | <1500                     | <1800                     |
| 31         | <1210                     | <1500                     | <1600                     | <1700                     | <2000                     |
| 32         | <1370                     | <1700                     | <1800                     | <1900                     | <2200                     |
| 33         | <1570                     | <1880                     | <2000                     | <2120                     | <2500                     |

*one newborn with BW >90th percentile (BW=2860 g)

Source: average BW of male infants (RCPCH UK-WHO Neonatal and Infant Close Monitoring Growth Chart 2009).  

**Table 2. Average percentiles of birth weight (BW, grams) in female newborns (N=29) in groups of the same gestational age (GA)**

| GA (weeks) | <10th percentile n BW (g) | <31st percentile n BW (g) | <50th percentile n BW (g) | <66th percentile n BW (g) | <90th percentile n BW (g) |
|------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| ≤28        | <810                      | <1040                     | <1190                     | <1150                     | <1350                     |
| 29         | <900                      | <1120                     | <1200                     | <1300                     | <1500                     |
| 30         | <1010                     | <1260                     | <1350                     | <1450                     | <1700                     |
| 31         | <1130                     | <1320                     | <1510                     | <1610                     | <1900                     |
| 32         | <1300                     | <1600                     | <1700                     | <1810                     | <2110                     |
| 33         | <1450                     | <1690                     | <1900                     | <1930                     | <2600                     |

Source: average BW of female infants (RCPCH UK-WHO Neonatal and Infant Close Monitoring Growth Chart 2009).

**Table 3. Birth weight (BW), gestational age (GA) and levels of insulin-like growth factor-1 (IGF-1) according to gender**

| Parameter | Male, N=42 | Female, N=29 | p and t values** |
|-----------|------------|--------------|------------------|
| BW (g)*   | 1796.0±410.80 | 1581.7±363.45 | p<0.05; t=2.022 |
| GA (weeks)* | 31.4±1.74    | 30.8±2.02    | p<0.05; t=1.321 |
| IGF-1 (mcg/L)* | 23.2±4.98   | 23.1±4.87    | p<0.05; t=1.284 |

*values expressed as mean ± SD; **Student's t-test
Table 5. Gestational age (GA) and levels of insulin-like growth factor-1 (IGF-1) in female newborns (N=29) with birth weight (BW) >50th percentile and BW <50th percentile

| Parameter | BW >50th percentile n=19 | BW <50th percentile n=10 | p and t values* |
|-----------|--------------------------|--------------------------|-----------------|
| GA (weeks)* | 30.5±2.09 | 31.5±1.78 | p>0.05; t=1.745 |
| IGF-1 (mcg/L)* | 23.2±2.09 | 22.8±3.46 | p>0.05; t=2.758 |

*values expressed as mean ± SD; "Student’s t-test

Table 6. Gestational age (GA) and levels of insulin-like growth factor-1 (IGF-1) in male newborns according to birth weight (BW) cut-off value of 1481 g (33rd percentile for the whole group)

| Parameter | BW >33rd percentile n=31 | BW <33rd percentile n=11 | p and t/U values** |
|-----------|--------------------------|--------------------------|--------------------|
| GA (weeks)* | 32.1±0.96 | 29.3±1.74 | p<0.001; t=3.251 |
| IGF-1 (mcg/L)* | 22.3 (21.09-25.60) | 18.7 (18.02-23.31) | p<0.05; U=49 |

**values expressed as mean ± SD; "Student’s t-test; **Mann-Whitney U test

Discussion and Conclusion

Intrauterine growth is a complex process involving maternal, placental and fetal factors of genetic, environmental and nutritional nature. BW has served as a surrogate marker of fetal growth, nutrition and health. In this study, we used BW as a marker of fetal growth.

A growth-restricted fetus/newborn is characterized by an increased rate of fetal and neonatal mortality and morbidity and an increased risk of chronic adult diseases such as neurodevelopmental outcome, cardiovascular disease, diabetes and obesity16-18.

Many authors have clearly established that IGF-1 is the main regulator of intrauterine growth, as confirmed by correlation between low BW and low cord serum IGF-111,19. However, some studies failed to show any association between intrauterine growth and IGF-17,20. Discrepancies in previous studies could partly be explained by difficulties in obtaining reliable measurements, common problems when studying newborns, especially preterms19.
In our study, we obtained blood samples at 33rd percentile uniformly to reduce the possibility of error and to ensure better comparison of the results.

Our results showed that there was no significant difference in IGF-1 level between male and female newborns. Other authors report that female newborns have higher IGF-1 levels than males, explaining it by the size at birth being a composite of factors determined by gender. Also, the IGF-1 levels in umbilical cord plasma were higher in female newborns, but contributed positively to BW in both sexes.

Our results showed that there was no statistically significant difference in IGF-1 levels between the newborns with BW <50th percentile and newborns with BW >50th percentile. The newborns (male and female) with BW <50th percentile had lower IGF-1 level than newborns with BW >50th percentile, but this difference was not statistically significant.

In the next step, the primary cohort was divided into two groups according to the cut-off 33rd percentile (BW 1481 g). We found a statistically significant between-group difference according to IGF-1 levels. Newborns with BW <33rd percentile had a significantly lower IGF-1 level than newborns with higher BW. Other authors have reported similar results, indicating that IGF-1 reflects concurrent short-term growth velocity in BW >33rd percentile newborns.

Our results showed that there was no statistically significant difference in IGF-1 levels according to gender. IGF-1 levels of newborns below and above the 50th percentile of BW according to GA showed no difference either. Only BW <33rd percentile newborns had a statistically significantly lower level of IGF-1. Based on our results, it is concluded that serum IGF-1 levels reflect intrauterine growth only in BW <33rd percentile newborns.

According to our results, similar levels of IGF-1 in both male and female newborns facilitate interpretation of results and suggest uniform protocols (in both genders) for the use of IGF-1 in the treatment of IUGR.

Acknowledgment

This work was supported by grant from the Ministry of Education and Science, Republic of Serbia (Project No. 175035).

References

1. Sharma D, Sharma P, Shastri S. Genetic, metabolic and endocrine aspects of intrauterine growth restriction: an update. J Matern Fetal Neonatal Med. 2017;30(19):2263-75. https://doi.org/10.1080/14767058.2016.1245285
2. Sferruzzi-Perrin AN, Vaughan OR, Forhead AJ, Fowden AL. Hormonal and nutritional drivers of intrauterine growth. Curr Opin Clin Nutr Metab Care. 2013;16(3):298-309. http://doi:10.1097/mco.0b013e32835e643
3. Kota SK, Gayatri K, Jammula S, Meher LK, Kota SK, Krishna SV, et al. Fetal endocrinology. Indian J Endocrinol Metab. 2013;17(4):568-79. http://doi:10.4103/2230-8210.113722
4. Singal SS, Nygard K, Grattan R, Jansson T, Gupta MB. Increased insulin-like growth factor binding protein-1 phosphorylation in decidualized stromal mesenchymal cells in human intrauterine growth restriction placentas. J Histochem Cytochem. 2018;66(9):617-630. http://doi:10.1369/0022155418772574
5. Orrù S, Nigro E, Mandola A, Albieri A, Buono P, Daniele A, et al. A functional interplay between IGF-1 and adiponectin. Int J Mol Sci. 2017;18(10):2145. http://doi:10.3390/ijms18102145
6. Löfqvist C, Hellgren G, Niskason A, Engström E, Ley D, Hansen-Pupp I; WINROP Consortium. Low postnatal serum IGF-1 levels are associated with bronchopulmonary dysplasia (BPD). Acta Paediatr. 2012;101(12):1211-6. http://doi:10.1111/j.1651-2227.2012.02826.x
7. Liegl R, Löfqvist C, Hellström A, Smith LE. IGF-1 in retinopathy of prematurity, a CNS neurovascular disease. Early Hum Dev. 2016;102:13-9. http://doi:10.1016/j.earlhumdev.2016.09.008
8. Hellsström A, Ley D, Hansen-Pupp I, Hallberg B, Löfqvist C, van Marter L, et al. Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development. Acta Paediatr. 2016;105(6):576-86. http://doi:10.1111/apa.13350.
9. Hallestrom A, Ley D, Hallberg B, Lofqvist C, Hansen-Pupp I, Ramenghi LA, et al. IGF-1 as a drug for preterm infants: a step-wise clinical development. Curr Pharm Des. 2017;23(38):5964-70. http://doi:10.2174/1381612823666171002114545
10. Agrogiannis GD, Sifakis S, Psatsouris ES, Konstantinidou AE. Insulin-like growth factors in embryonic and fetal growth and skeletal development. Mol Med Rep. 2014;10(2):579-84. http://doi:10.3892/mmr.2014.2258
11. Yakar S, Isaksson O. Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: lessons from mouse models. Growth Horm IGF Res. 2016;28:26-42. http://doi:10.1016/j.ghir.2015.09.004
12. Ley D, Hansen-Pupp I, Niklasson A, Dibello M, Friberg LE, Borg J, et al. Longitudinal infusion of a complex of insulin-like growth factor-1 and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res. 2013;73(1):68-74. http://doi:10.1038/pr.2012.146
13. Dysinger M, Marusov G, Fraser S. Quantitative analysis of four protein biomarkers: an automated microfluidic cartridge-based method and its comparison to colorimetric ELISA. J Im-
Sažetak

POVEZANOST INZULINU SLIČNOG FAKTORA RASTA TIP 1 I INTRAUTERINOG RASTA

L. Banjac, J. Kotur-Stevuljević, T. Gojković, V. Bokan-Mirković, G. Banjac i G. Banjac

Inzulinu sličan faktor rasta (IGF-1) je jedan od čimbenika koji utječu na intrauterin rast. Serumne razine IGF-1 su smanjene u fetusima s intrauterinim zastojem rasta. Cilj našega istraživanja bio je ispitati odnos između razine IGF-1 u nedonoščadi i intrauterinog rasta izraženog kao porođajna težina (PT). Istraživanje je provedeno kao presječna studija. U studiju je bilo uključeno 71 nedonošća gestacijske dobi (GD) ≤33 tjedna. Kvantitativno određivanje IGF-1 provedeno je u 33. postmenstruacijskom tjednu (pmt) radi bolje usporedivosti rezultata. Za kvantitativno određivanje IGF-1 rabili smo enzimski imunosorbentni test. Naši rezultati pokazali su da je srednja razina IGF-1 u nedonoščadi u 33. pmt iznosila 23,1±4,56 (raspon 15,44-39,75) μg/L. Nije bilo razlike u vrijednostima IGF-1 između muške (23,1±4,98 μg/L) i ženske (23,1±4,87 μg/L) nedonoščadi. Također nije bilo značajne razlike u srednjim razinama IGF-1 između nedonoščadi s PT <50. i PT >50. percentila za GD (p>0,50). Nedonoščad s niskom PT (<33. percentila) imala su statistički značajno nižu razinu IGF-1. Na temelju naših rezultata može se zaključiti da serumna razina IGF-1 odražava intrauterin rast samo u nedonoščadi male PT (<33. percentila), što bi mogao biti koristan podatak za buduću uporabu IGF-1 u terapijske svrhe.

Ključne riječi: Novorođeni; Inzulinni slični faktor rasta I; Fetusni rast, retardacija; Presječna istraživanja